Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 results highlighted by a 196% year-over-year increase in Nociscan scan volumes, reflecting accelerating clinical adoption and integration into clinical workflows. The company also achieved 64% sequential growth from Q4 2025, driven by new account activation and deeper utilization within existing sites.
The Nociscan platform uses biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain. With approximately 5.8 million lumbar MRIs performed annually in the U.S. for low back pain, Aclarion sees a potential $2 billion market opportunity for its technology.
Key catalysts include reimbursement progress in the U.K., where Nociscan is now covered by Vitality, AXA, and Aviva—three of the four largest private insurers. The company launched a targeted direct-to-patient campaign featuring Mr. John Sutcliffe, Consultant Spinal Neurosurgeon at The London Clinic. In the U.S., Aclarion continues to engage payers through its Nociscan Reimbursement Program.
Clinical development remains on track with the CLARITY randomized trial, designed to validate Nociscan's clinical utility in guiding treatment decisions. Preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. Seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials are underway to support reimbursement discussions.
Aclarion strengthened its intellectual property portfolio with a new patent covering the use of AI in workflows of future products. The company now holds 64 issued and pending patents worldwide.
Financially, Aclarion is well-positioned with $19.0 million in cash, no debt, and a clean capital structure as of March 31, 2026. The company announced a $2.5 million share repurchase program and believes existing cash resources are sufficient to fund operations into the second half of 2027.
Brent Ness, CEO of Aclarion, stated, "Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market."
For more information about Aclarion and Nociscan, visit the company's website or view the latest news in the company's newsroom.
